Vital Signs - Embryonic Stem Cells: High Potential and Controversy

Vital Signs - Embryonic Stem Cells: High Potential and Controversy

 

RELEASE DATE
01-Dec-2008
REGION
North America
Research Code: 9561-00-7C-00-00
SKU: HC00555-NA-MR_04027
AvailableYesPDF Download

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
HC00555-NA-MR_04027

$1,500.00

$1,125.00save 25 %

DownloadLink
ENQUIRE NOW

Description

This issue of Vital Signs, released on December 1, 2008, provides an strategic overview of trends and issues surrounding embryonic stem cell development in the U.S. Additionally, a company spotlight is provided for Seattle Genetics, a biotechnology company focused on the development and commercialization of therapeutic monoclonal antibodies for the treatment of autoimmune diseases and cancer. Reimbursement and regulatory news from the FDA is also provided for the week of November 17, 2008.

Table of Contents

This week's issue:

Related Research
This issue of Vital Signs, released on December 1, 2008, provides an strategic overview of trends and issues surrounding embryonic stem cell development in the U.S. Additionally, a company spotlight is provided for Seattle Genetics, a biotechnology company focused on the development and commercialization of therapeutic monoclonal antibodies for the treatment of autoimmune diseases and cancer. Reimbursement and regulatory news from the FDA is also provided for the week of November 17, 2008.
More Information
No Index Yes
Podcast No
Industries Healthcare
WIP Number 9561-00-7C-00-00
Is Prebook No